Doxycycline hyclate tablets recalled after stability testing failed dissolution specifications
Acella Pharmaceuticals is recalling 4,680 five-hundred-count bottles of Doxycycline Hyclate Tablets USP 100 mg after stability testing found the lot did not meet dissolution specifications.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: Scored 2 as a specification failure: the record states only that dissolution specifications were not met, without describing a health consequence or reporting injury.
Plain-English summary
Doxycycline Hyclate Tablets, USP 100 mg, in 500-count bottles, distributed by Acella Pharmaceuticals of Alpharetta, Georgia, are being recalled for failed dissolution specifications. Stability testing found that the lot did not meet those specifications.
The recall covers 4,680 bottles from lot P24ZLK1, expiring 31 May 2027, carrying NDC 42192-501-05. The product was distributed nationwide in the United States. The FDA has classified the recall as Class II.
The enforcement record states the dissolution failure without describing a health consequence, and reports no injuries.
Doxycycline is a prescription antibiotic, so patients holding the affected lot should contact their pharmacy or prescriber about a replacement rather than stopping treatment on their own.
The recalled product
- Product
- DOXYCYCLINE (DOXYCYCLINE HYCLATE)
- Brand
- DOXYCYCLINE
- Manufacturer
- Acella Pharmaceuticals, LLC
- Category
- Drug — Antibiotic
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: P24ZLK1
- Exp 5/31/2027
UPCs (1)
- 0342192501058
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · DOXYCYCLINE
- ModerateDoxycycline Capsules Recalled Due to Temperature Storage Deviation
FDA (Drugs) · 2024-01-03
- ModerateDoxycycline Capsules Recalled for Temperature Control Deviation
FDA (Drugs) · 2022-06-15
- ModeratePD-Rx Recalls Doxycycline Hyclate Tablets for Failed Dissolution Specifications
FDA (Drugs) · 2020-06-03
- SevereSun Pharmaceutical Recalls Doxycycline Capsules Due to Manufacturing Deviations
FDA (Drugs) · 2020-03-25
- ModerateSun Pharmaceutical Recalls Doxycycline Capsules Due to Manufacturing Deviations
FDA (Drugs) · 2020-03-25
Same manufacturer · Acella Pharmaceuticals, LLC
See all →- SevereNaproxen Oral Suspension Recalled for Lead and Lithium Contamination
FDA (Drugs) · 2026-05-13
- ModeratePrescription skin cleanser recalled nationwide due to subpotency
FDA (Drugs) · 2024-05-15
- ModerateAcella Recalls Sodium Sulfacetamide Cleansing Pads for Subpotency
FDA (Drugs) · 2022-12-07
- LowPhenytoin Sodium Injection Recalled for Missing Barcode on Vial Label
FDA (Drugs) · 2022-11-30
- LowPhenytoin Sodium Injection Recalled for Missing Vial Barcode
FDA (Drugs) · 2022-11-30
Same hazard · failed dissolution
See all →- ModerateNovartis Recalls Diovan Valsartan Tablets Due to Failed Dissolution Specifications
FDA (Drugs) · 2026-08-19
- LowSupernus Recalls Trokendi XR Capsules for Failed Dissolution Specifications
FDA (Drugs) · 2026-07-29
- HighAscend amlodipine and olmesartan tablets failed dissolution specifications
FDA (Drugs) · 2026-06-10
- HighLannett niacin extended-release tablets failed dissolution specifications during stability
FDA (Drugs) · 2026-06-10
- HighMajor Pharmaceuticals memantine extended-release capsules fail dissolution specifications
FDA (Drugs) · 2026-04-22